grarpamp at gmail.com
Mon Nov 21 16:25:00 PST 2022
"Grade-A Gaslighting": FDA Says Anti-Ivermectin Campaign Was 'Just A
The US Food and Drug Administration (FDA), which mocked Americans for
taking Ivermectin to treat Covid-19, now says their campaign telling
people to "stop" taking it was informal and just a recommendation,
according to an argument made by government lawyers during a recent
"The cited statements were not directives. They were not mandatory.
They were recommendations. They said what parties should do. They
said, for example, why you should not take ivermectin to treat
COVID-19. They did not say you may not do it, you must not do it. They
did not say it’s prohibited or it’s unlawful. They also did not say
that doctors may not prescribe ivermectin," Isaac Belfer, one of the
lawyers, told the court during the Nov. 1 hearing in federal court in
Texas according to the Epoch Times.
"They use informal language, that is true," Belfer continued, adding
"it’s conversational but not mandatory."
Yet, in 2021 the FDA created a web page titled "Why You Should Not Use
Ivermectin to Treat or Prevent COVID-19," before then tweeting: "You
are not a horse. You are not a cow. Seriously, y’all. Stop it."
You are not a horse. You are not a cow. Seriously, y'all. Stop it.
— U.S. FDA (@US_FDA) August 21, 2021
A second Twitter campaign stated: "Hold your horses, y’all. Ivermectin
may be trending, but it still isn’t authorized or approved to treat
In a separate page noted by the Times, the FDA said: “Q: Should I take
ivermectin to prevent or treat COVID-19? A: No.”
Jared Kelson, an attorney representing the plaintiffs, told the
court during the hearing that that informal claim “doesn’t explain the
language they actually used: ‘Stop it. Stop it with the ivermectin.'”
The FDA’s actions “clearly convey that this is not an acceptable
way to treat these patients,” he argued.
Plaintiffs in the case include Dr. Paul Marik, who began utilizing
ivermectin in his COVID-19 treatment protocol in 2020 while he was
chief of pulmonary and critical care medicine at Eastern Virginia
Medical School and director of the intensive care unit at Sentara
Norfolk General Hospital.
After the FDA’s statements, Marik was told to remove the protocol
from the school’s servers while Sentara issued a memorandum to
hospitals telling them to stop using ivermectin against COVID-19, with
a citation to the FDA. -Epoch Times
As Justin Heart, author of "Gone Viral," notes, the FDA is doing some
"grade A gaslighting now."
Wow. Just wow. @US_FDA doing some grade A gaslighting now. “It was
just a recommendation!” pic.twitter.com/qzKpjTpBIa
— Justin Hart (@justin_hart) November 20, 2022
This widely prescribed anti-parasitic which is also used in horses has
shown massive efficacy worldwide in the treatment of mild and moderate
cases of Covid-19, plus as a prophylactic. India's Uttar Pradesh
province, with a population of over 200 million, says that widespread
early use of Ivermectin 'helped keep positivity [and] deaths low.'
(source, May 12th, 2021)
Separately, there have been several studies funded by the Indian
government, primarily conducted through their largest govt. public
medical university (AIIMS).
Role of ivermectin in the prevention of SARS-CoV-2 infection among
healthcare workers in India: A matched case-control study (source)
Conclusion: Two-dose ivermectin prophylaxis at a dose of 300 μg/kg
with a gap of 72 hours was associated with a 73% reduction of
SARS-CoV-2 infection among healthcare workers for the following month.
Ivermectin as a potential treatment for mild to moderate COVID-19
– A double blind randomized placebo-controlled trial (source)
Conclusion: There was no difference in the primary outcome i.e.
negative RT-PCR status on day 6 of admission with the use of
ivermectin. However, a significantly higher proportion of patients
were discharged alive from the hospital when they received ivermectin.
Clinical Research Report Ivermectin in combination with
doxycycline for treating COVID-19 symptoms: a randomized trial
(source, double-blind randomized, peer-reviewed)
Discussion: In the present study, patients with mild or moderate
COVID-19 infection treated with ivermectin in combination with
doxycycline generally recovered 2 days earlier than those treated with
placebo. The proportion of patients responding within 7 days of
treatment was significantly higher in the treatment group than in the
placebo group. The proportions of patients who remained symptomatic
after 12 days of illness and who experienced disease progression were
significantly lower in the treatment group than in the placebo group.
Here are more human studies from other countries on the 'horse dewormer':
Sharp Reductions in COVID-19 Case Fatalities and Excess Deaths in
Peru in Close Time Conjunction, State-By-State, with Ivermectin
Treatments (source, peer-reviewed, University of Toronto, Universidad
For the 24 states with early IVM treatment (and Lima), excess
deaths dropped 59% (25%) at +30 days and 75% (25%) at +45 days after
day of peak deaths. Case fatalities likewise dropped sharply in all
states but Lima
The effect of early treatment with ivermectin on viral load,
symptoms and humoral response in patients with non-severe COVID-19: A
pilot, double-blind, placebo-controlled, randomized clinical trial
(source, University of Barcelona, peer-reviewed)
Findings: Patients in the ivermectin group recovered earlier from
hyposmia/anosmia (76 vs 158 patient-days; p < 0.001).
A Comparative Study on Ivermectin-Doxycycline and
Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients (source -
peer reviewed, though not govt funded)
Conclusion: According to our study, the
Ivermectin-Doxycycline combination therapy has better symptomatic
relief, shortened recovery duration, fewer adverse effects, and
superior patient compliance compared to the
Hydroxychloroquine-Azithromycin combination. Based on this study's
outcomes, the Ivermectin-Doxycycline combination is a superior
choice for treating patients with mild to moderate COVID-19
A five-day course of ivermectin for the treatment of COVID-19 may
reduce the duration of illness (source, peer-reviewed double blind
randomized, though small sample size)
Discussion: A 5-day course of ivermectin resulted in an earlier
clearance of the virus compared to placebo (p = 0.005), thus
indicating that early intervention with this agent may limit viral
replication within the host. In the 5-day ivermectin group, there was
a significant drop in CRP and LDH by day 7, which are indicators of
Meanwhile, There are currently 86 ongoing or completed clinical trials
on Ivermectin around the world.
More information about the cypherpunks